Lung Cancer

dr desai pulmonologist :: Article Creator Dr. Ashok Dahyabhai Desai, Pulmonologist Dr. Ashok Dahyabhai Desai, Pulmonologist in Delhi, DelhiContact Details for Consultation Dr. Ashok Dahyabhai Desai, a specialist in Pulmonology based and practicing in Delhi. If you are the doctor associated with this profile, we invite you to register and claim your profile for free to help us to get it verified. If the information requires to be updated please click here. This will ensure that your patient's can locate you for an appointment. Advertisement Advertisement Advertisement Search for Doctors from other specialities in Delhi OUR PREMIUM PULMONOLOGISTS Here is a list of verified Pulmonologists from India who have a virtual clinic on Medindia and provide online video consultation for patients. Dr. Chetan Sharma MBBS, MD 14 years experience Ramayana H...

stage 4 leukemia life expectancy :: Article Creator Stages Of Chronic Lymphocytic Leukemia (CLL) Medically reviewed by Steffini Stalos, DOMedically reviewed by Steffini Stalos, DO Chronic lymphocytic leukemia (CLL) is a type of cancer affecting a type of white blood cell in the blood and bone marrow. It often progresses slowly and is diagnosed most often during routine blood testing. Understanding the stages of CLL—from stage 0 to 4—can help you navigate a CLL diagnosis. Although each increase in stage represents disease progression, you have treatment options and ways to manage symptoms to help provide a good quality of life. This article will describe each stage's prognosis, symptoms, and treatment options. AleksandarNakic / Getty Images Beginning to End Stages of CLL Once diagnosed, chronic lymphocytic leukemia is staged to determine how advanced the disease is and to help determine the best treatment. The most common stagi...

lung cancer spread to liver :: Article Creator Are Liver Cysts A Sign Of Cancer? You may not post any unlawful, threatening, libelous, defamatory, obscene, pornographic or other material that would violate the law. By submitting your question, you hereby give CNN the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your questions(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. CNN Privacy Statment. Surgery For Sarcoma That Has Spread ...

stage 4 colon cancer metastasized to liver and lungs prognosis :: Article Creator Stage 4 Breast Cancer Survival Rates And Life Expectancy Life expectancy for stage 4 breast cancer can vary. Breast cancer that's spread to the lungs, for example, has a five-year survival rate of 10.94%. Other factors that affect life expectancy include age, cancer subtype, tumor size, and treatments. Stage 4 breast cancer refers to the spread of breast cancer outside the breasts and surrounding lymph nodes. The most common sites of spread include the bones, lungs, liver, and brain. Breast cancer doesn't become bone or lung cancer if it spreads to these body parts. It's still breast cancer. Stage 4 breast cancer, or metastatic breast cancer, is the most severe and life-threatening type. There's no cure, but treatment can improve survival rates. Read on to learn how long you can live with breast cancer that has metastasized. There...

stage 2 esophageal cancer :: Article Creator Surgery Plus FLOT: A Game Changer For Esophageal Cancer? Patrick Boland, MD, discussed the practice-changing implications of the phase 3 ESOPEC study comparing FLOT vs CROSS regimens for the treatment of esophageal adenocarcinoma. The phase 3 ESOPEC study (NCT02509286) investigated the best approach for treating esophageal adenocarcinoma that can be surgically removed. The study was a head-to-head comparison of neoadjuvant chemoradiation, or CROSS, vs perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT). The study found that FLOT resulted in significantly better survival rates compared with CROSS. After a median follow-up of almost 5 years, patients receiving FLOT lived a median of 66 months, while those receiving CROSS lived a median of 37 months. The chance of surviving 3 years was also higher with FLOT (57.4%) compared with CROSS (50.7%). Additionally, FLOT s...